US 12,410,484 B2
Method for cold plasma induced cell death in breast cancer cells by 8-oxoG modification and degradation of histone mRNA
Jerome Canady, Takoma Park, MD (US); Saravana Murthy, Takoma Park, MD (US); Xiaoqian Cheng, Takoma Park, MD (US); and Taisen Zhuang, Takoma Park, MD (US)
Assigned to Jerome Canady Research Institute for Advanced Biological and Technological Sciences, Takoma Park, MD (US)
Appl. No. 18/576,506
Filed by Jerome Canady Research Institute for Advanced Biological and Technological Sciences, Takoma Park, MD (US)
PCT Filed Jul. 5, 2022, PCT No. PCT/US2022/036133
§ 371(c)(1), (2) Date Jan. 4, 2024,
PCT Pub. No. WO2023/283194, PCT Pub. Date Jan. 12, 2023.
Claims priority of provisional application 63/218,449, filed on Jul. 5, 2021.
Prior Publication US 2024/0263244 A1, Aug. 8, 2024
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/158 (2013.01)] 8 Claims
 
1. A method for monitoring levels of oxidized histone mRNA in breast cancer cells, comprising the steps of:
treating breast cancer cells with cold atmospheric plasma (CAP);
isolating histone mRNA from the CAP-treated breast cancer cells;
incubating the histone mRNA with a peptide according to SEQ ID NO: 1; and
determining the levels of oxidized histone mRNA by measuring a fluorescence intensity.